AURKA and neoplasm: AURKA inhibition using LY compounds has shown anti-tumor activity in pre-clinical studies [22] which has led to further investigation for a variety of solid tumors including advanced EGFR mutant non-squamous lung cancer (NCT05017025), small cell lung cancer (NCT03898791), metastatic breast cancer (NCT03955939), and relapsed/refractory neuroblastoma (NCT04106219).